我武生物
(300357)
| 流通市值：96.57亿 | | | 总市值：104.46亿 |
| 流通股本：4.84亿 | | | 总股本：5.24亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 1,145,510,054.31 | 1,118,840,884.89 | 1,086,477,440.79 | 1,223,125,711.39 |
| 应收票据及应收账款 | 188,768,169.43 | 177,902,072.28 | 247,441,098.85 | 198,902,387.83 |
| 其中：应收票据 | 18,899,090.95 | 24,887,375.01 | 17,596,301.06 | 13,711,895.36 |
| 应收账款 | 169,869,078.48 | 153,014,697.27 | 229,844,797.79 | 185,190,492.47 |
| 应收款项融资 | 42,048,678.12 | 73,141,123.3 | 68,712,659.39 | 42,790,657.93 |
| 预付款项 | 8,194,463.19 | 3,275,311.03 | 5,271,617.09 | 4,959,097 |
| 其他应收款合计 | 7,646,777.24 | 6,828,428.02 | 8,010,838.23 | 7,956,522.12 |
| 存货 | 57,466,278.42 | 57,733,424.33 | 52,513,651.44 | 61,756,217.31 |
| 其他流动资产 | 19,981,618.78 | 17,675,683.95 | 15,330,282.5 | 13,818,293.73 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,610,271,076.53 | 1,651,487,813.7 | 1,648,880,999.51 | 1,648,225,882.54 |
| 非流动资产: | | | | |
| 长期股权投资 | 72,307,930.03 | 72,512,422.61 | 72,769,757.9 | 73,107,973.42 |
| 其他权益工具投资 | 5,428,577.14 | 5,428,577.14 | 5,428,577.14 | 5,428,577.14 |
| 固定资产 | 432,224,056.16 | 443,494,642.92 | 448,464,228.4 | 450,290,754.24 |
| 在建工程 | 353,274,050.4 | 323,157,347.8 | 311,238,189.23 | 275,020,564.34 |
| 使用权资产 | 6,003,043.51 | 13,442,162.59 | 13,845,559.24 | 24,995,487.53 |
| 无形资产 | 159,144,734.42 | 162,786,514.35 | 152,248,173.14 | 154,873,421.8 |
| 开发支出 | 20,407,157.91 | 18,744,533.16 | 30,664,553.39 | 29,011,293.18 |
| 长期待摊费用 | 6,614,050.85 | 6,525,569.32 | 6,609,896.99 | 6,916,442.59 |
| 递延所得税资产 | 5,821,342.66 | 5,601,021.68 | 6,501,058.95 | 5,947,504.24 |
| 其他非流动资产 | 4,012,275.67 | 5,944,328.93 | 4,394,465.72 | 7,789,820 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,065,237,218.75 | 1,057,637,120.5 | 1,052,164,460.1 | 1,033,381,838.48 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,675,508,295.28 | 2,709,124,934.2 | 2,701,045,459.61 | 2,681,607,721.02 |
| 流动负债: | | | | |
| 短期借款 | 5,051,595.14 | 12,628,987.85 | 37,215,612.61 | 44,365,782 |
| 应付票据及应付账款 | 29,538,973.66 | 47,771,012.62 | 8,165,059.01 | 7,552,205.38 |
| 应付账款 | 29,538,973.66 | 47,771,012.62 | 8,165,059.01 | 7,552,205.38 |
| 合同负债 | 556,829.8 | 506,680.97 | 1,383,934.89 | 1,422,535.64 |
| 应付职工薪酬 | 20,760,967.28 | 27,733,155.93 | 24,219,485.75 | 19,790,316.42 |
| 应交税费 | 15,829,279.25 | 18,695,858.83 | 30,075,811.66 | 17,052,688.28 |
| 其他应付款合计 | 8,808,056.32 | 70,216,598.67 | 57,192,942.56 | 151,621,910.07 |
| 应付股利 | - | 52,358,400 | - | 96,863,038.72 |
| 一年内到期的非流动负债 | 3,940,346.22 | 5,030,864.8 | 5,141,140.15 | 6,829,731.61 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 84,486,047.67 | 182,583,159.67 | 163,393,986.63 | 248,635,169.4 |
| 非流动负债: | | | | |
| 租赁负债 | 1,373,570.57 | 7,930,345.74 | 8,365,071.56 | 17,748,217.73 |
| 递延收益 | 33,095,773.83 | 33,534,016.89 | 33,972,259.95 | 34,410,503.01 |
| 递延所得税负债 | 98,170.79 | 172,704.97 | 177,802.81 | 176,735.38 |
| 其他非流动负债 | 26,075,031.58 | 26,075,031.58 | 25,796,286.43 | 25,796,286.43 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 60,642,546.77 | 67,712,099.18 | 68,311,420.75 | 78,131,742.55 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 145,128,594.44 | 250,295,258.85 | 231,705,407.38 | 326,766,911.95 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 523,584,000 | 523,584,000 | 523,584,000 | 523,584,000 |
| 资本公积 | 128,194,388.22 | 128,194,388.22 | 128,194,388.22 | 128,194,388.22 |
| 其他综合收益 | 36,157.34 | 37,155.35 | 29,429.14 | 5,406,022.28 |
| 盈余公积 | 270,715,165.14 | 270,715,165.14 | 270,715,165.14 | 270,715,165.14 |
| 未分配利润 | 1,505,518,060.44 | 1,431,175,993.3 | 1,437,966,005.06 | 1,314,943,005.56 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 2,428,047,771.14 | 2,353,706,702.01 | 2,360,488,987.56 | 2,242,842,581.2 |
| 少数股东权益 | 102,331,929.7 | 105,122,973.34 | 108,851,064.67 | 111,998,227.87 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 2,530,379,700.84 | 2,458,829,675.35 | 2,469,340,052.23 | 2,354,840,809.07 |
| 负债和股东权益合计 | 2,675,508,295.28 | 2,709,124,934.2 | 2,701,045,459.61 | 2,681,607,721.02 |
| 公告日期 | 2025-04-19 | 2025-04-19 | 2024-10-24 | 2024-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |